![]() | |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 3.6–5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.007.788 |
Chemical and physical data | |
Formula | C6H8ClNS |
Molar mass | 161.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Clomethiazole (also called chlormethiazole) is a sedative and hypnotic originally developed by Hoffmann-La Roche in the 1930s.[3] The drug is typically used in treating and preventing symptoms of acute alcohol withdrawal, anxiety and as a sedative-hypnotic.
It is structurally related to thiamine (vitamin B1), but acts like a sedative, hypnotic, anxiolytic, muscle relaxant and anticonvulsant, having the same mechanism of action as traditional barbiturates. It is also used for the management of agitation, restlessness, and Parkinson's disease. In the UK, it is sold under the brand Heminevrin (AstraZeneca Pharmaceuticals). Other brand names include Nevrin in Romania, Distraneurin in Germany and Distraneurine in Spain. The drug is marketed either as a free base in an oily solution containing 192 mg in capsule form, or as clomethiazole edisylate syrup. Due to its high toxicity compared to benzodiazepines it is not recommended as a first-line treatment for any indication and is particularly dangerous to patients with an elevated risk for drug abuse such as those with a personal or familial history of addiction.